Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free DMAA Stock Alerts

Drugs Made In America Acquisition (DMAA) Competitors

Drugs Made In America Acquisition logo
$10.61 -0.01 (-0.09%)
As of 10:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

DMAA vs. CSR, ESRT, TIGR, RPC, and JBGS

Should you buy Drugs Made In America Acquisition stock or one of its competitors? MarketBeat compares Drugs Made In America Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Drugs Made In America Acquisition include Centerspace (CSR), Empire State Realty Trust (ESRT), UP Fintech (TIGR), Ridgepost Capital (RPC), and JBG SMITH Properties (JBGS). These companies are all part of the "trading" industry.

How does Drugs Made In America Acquisition compare to Centerspace?

Centerspace (NYSE:CSR) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Centerspace has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Centerspace$273.66M3.54$17.59M$0.45128.15
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

Centerspace has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Centerspace has a net margin of 2.93% compared to Drugs Made In America Acquisition's net margin of 0.00%. Centerspace's return on equity of 0.94% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Centerspace2.93% 0.94% 0.40%
Drugs Made In America Acquisition N/A N/A N/A

Centerspace presently has a consensus target price of $68.80, indicating a potential upside of 19.30%. Given Centerspace's stronger consensus rating and higher possible upside, research analysts clearly believe Centerspace is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Centerspace
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.29
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Drugs Made In America Acquisition had 1 more articles in the media than Centerspace. MarketBeat recorded 1 mentions for Drugs Made In America Acquisition and 0 mentions for Centerspace. Drugs Made In America Acquisition's average media sentiment score of 1.87 beat Centerspace's score of 0.32 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
Centerspace Neutral
Drugs Made In America Acquisition Very Positive

79.0% of Centerspace shares are held by institutional investors. 0.5% of Centerspace shares are held by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Centerspace beats Drugs Made In America Acquisition on 9 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Empire State Realty Trust?

Empire State Realty Trust (NYSE:ESRT) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Empire State Realty Trust has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Empire State Realty Trust$768.27M1.22$47.60M$0.2620.87
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

Empire State Realty Trust currently has a consensus price target of $5.92, suggesting a potential upside of 9.06%. Given Empire State Realty Trust's stronger consensus rating and higher possible upside, analysts clearly believe Empire State Realty Trust is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Empire State Realty Trust
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

67.1% of Empire State Realty Trust shares are owned by institutional investors. 15.2% of Empire State Realty Trust shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Empire State Realty Trust has a net margin of 5.09% compared to Drugs Made In America Acquisition's net margin of 0.00%. Empire State Realty Trust's return on equity of 2.19% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Empire State Realty Trust5.09% 2.19% 0.93%
Drugs Made In America Acquisition N/A N/A N/A

In the previous week, Empire State Realty Trust and Empire State Realty Trust both had 1 articles in the media. Drugs Made In America Acquisition's average media sentiment score of 1.87 beat Empire State Realty Trust's score of 1.02 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
Empire State Realty Trust Positive
Drugs Made In America Acquisition Very Positive

Empire State Realty Trust has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Summary

Empire State Realty Trust beats Drugs Made In America Acquisition on 9 of the 10 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to UP Fintech?

Drugs Made In America Acquisition (NASDAQ:DMAA) and UP Fintech (NASDAQ:TIGR) are both small-cap trading companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

UP Fintech has a consensus target price of $9.23, suggesting a potential upside of 90.71%. Given UP Fintech's stronger consensus rating and higher probable upside, analysts clearly believe UP Fintech is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
UP Fintech
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

UP Fintech has a net margin of 17.64% compared to Drugs Made In America Acquisition's net margin of 0.00%. UP Fintech's return on equity of 13.90% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Drugs Made In America AcquisitionN/A N/A N/A
UP Fintech 17.64%13.90%1.30%

In the previous week, UP Fintech had 9 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 10 mentions for UP Fintech and 1 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.87 beat UP Fintech's score of 0.44 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company Overall Sentiment
Drugs Made In America Acquisition Very Positive
UP Fintech Neutral

UP Fintech has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A
UP Fintech$612.07M1.50$170.90M$0.608.07

9.0% of UP Fintech shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Drugs Made In America Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, UP Fintech has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Summary

UP Fintech beats Drugs Made In America Acquisition on 10 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Ridgepost Capital?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Ridgepost Capital (NYSE:RPC) are both small-cap financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Drugs Made In America Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Ridgepost Capital has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Ridgepost Capital has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A
Ridgepost Capital$304.70M3.01$19.50M$0.2238.11

Ridgepost Capital has a consensus target price of $12.00, indicating a potential upside of 43.11%. Given Ridgepost Capital's stronger consensus rating and higher possible upside, analysts clearly believe Ridgepost Capital is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ridgepost Capital
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Ridgepost Capital had 1 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 2 mentions for Ridgepost Capital and 1 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.87 beat Ridgepost Capital's score of 0.00 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company Overall Sentiment
Drugs Made In America Acquisition Very Positive
Ridgepost Capital Neutral

48.0% of Ridgepost Capital shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Comparatively, 11.5% of Ridgepost Capital shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ridgepost Capital has a net margin of 7.99% compared to Drugs Made In America Acquisition's net margin of 0.00%. Ridgepost Capital's return on equity of 24.58% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Drugs Made In America AcquisitionN/A N/A N/A
Ridgepost Capital 7.99%24.58%10.56%

Summary

Ridgepost Capital beats Drugs Made In America Acquisition on 11 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to JBG SMITH Properties?

JBG SMITH Properties (NYSE:JBGS) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

JBG SMITH Properties has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Drugs Made In America Acquisition has lower revenue, but higher earnings than JBG SMITH Properties.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JBG SMITH Properties$498.60M1.70-$139.06M-$1.87N/A
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

In the previous week, JBG SMITH Properties had 1 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 2 mentions for JBG SMITH Properties and 1 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 1.87 beat JBG SMITH Properties' score of -0.06 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
JBG SMITH Properties Neutral
Drugs Made In America Acquisition Very Positive

Drugs Made In America Acquisition has a net margin of 0.00% compared to JBG SMITH Properties' net margin of -22.16%. Drugs Made In America Acquisition's return on equity of 0.00% beat JBG SMITH Properties' return on equity.

Company Net Margins Return on Equity Return on Assets
JBG SMITH Properties-22.16% -9.32% -2.53%
Drugs Made In America Acquisition N/A N/A N/A

98.5% of JBG SMITH Properties shares are owned by institutional investors. 11.9% of JBG SMITH Properties shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

JBG SMITH Properties presently has a consensus target price of $18.50, suggesting a potential upside of 26.97%. Given JBG SMITH Properties' higher probable upside, analysts clearly believe JBG SMITH Properties is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JBG SMITH Properties
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

JBG SMITH Properties beats Drugs Made In America Acquisition on 6 of the 10 factors compared between the two stocks.

Get Drugs Made In America Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for DMAA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAA vs. The Competition

Export
MetricDrugs Made In America AcquisitionInvestment Offices IndustryFinancial SectorNASDAQ Exchange
Market Cap$257.61M$324.64M$5.93B$12.32B
Dividend YieldN/AN/A5.29%5.66%
P/E RatioN/A2.2516.4224.65
Price / SalesN/A188.431,754.83171.03
Price / CashN/A135.8348.6737.92
Price / BookN/A348.546.576.84
Net IncomeN/A-$66.73M$1.13B$337.45M
7 Day PerformanceN/A-0.42%1.55%2.48%
1 Month Performance0.27%2.12%2.00%4.36%
1 Year PerformanceN/A3.26%21.01%32.45%

Drugs Made In America Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DMAA
Drugs Made In America Acquisition
1.3452 of 5 stars		$10.61
-0.1%		N/AN/A$257.61MN/AN/A2
CSR
Centerspace
3.7171 of 5 stars		$59.23
-1.3%		$68.80
+16.2%		-8.2%$1.01B$273.66M131.62470
ESRT
Empire State Realty Trust
1.9753 of 5 stars		$5.28
+0.3%		$6.25
+18.4%		-36.5%$906.98M$768.27M20.30670
TIGR
UP Fintech
3.1728 of 5 stars		$4.48
-5.9%		$9.23
+106.1%		-42.6%$902.97M$612.07M7.471,346
RPC
Ridgepost Capital
3.7841 of 5 stars		$8.05
-1.1%		$12.00
+49.0%		N/A$891.14M$304.70M36.60180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DMAA) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Elon’s new "tollbooth"
The upcoming SpaceX IPO - reported for June 12 - is valued at $1.75 trillion. But one analyst says fighting ov...
Weiss Ratings | Sponsoredtc pixel